Followers | 83 |
Posts | 5662 |
Boards Moderated | 1 |
Alias Born | 10/17/2006 |
Thursday, May 11, 2017 1:43:36 PM
There's more turmoil to report at struggling XBiotech (XBIT) . The biotech company's No. 2 executive resigned last week.
Kelly Thornburg, XBiotech's senior vice president of operations, submitted his resignation letter on May 5 and left the company immediately. Thornburg's exit was disclosed in a note at the bottom of the XBiotech 10-Q filed with the Securities and Exchange Commission on Wednesday night.
https://www.thestreet.com/story/14130753/1/xbiotech-no-2-executive-resigns-leaving-struggling-biotech-without-top-operations-chief.html
Recent XBIT News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 04:57:05 PM
- XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer • GlobeNewswire Inc. • 06/18/2024 03:35:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 03:27:20 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 05:36:43 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 05:01:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 03:48:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 02:00:25 PM
- XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus • GlobeNewswire Inc. • 01/04/2024 02:00:00 PM
- XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus • GlobeNewswire Inc. • 01/04/2024 02:00:00 PM
- Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis • GlobeNewswire Inc. • 11/14/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 07:41:46 PM
- XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke • GlobeNewswire Inc. • 09/26/2023 01:00:00 PM
- XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer • GlobeNewswire Inc. • 08/30/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 03:18:47 PM
- XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial • GlobeNewswire Inc. • 08/08/2023 03:47:05 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM